Sato Kazuki, Ohira Hiroshi, Horinouchi Takahiro, Nakaya Toshitaka, Mazaki Yuichi, Sugimoto Ayako, Watanabe Taku, Tsujino Ichizo, Nishimura Masaharu
First Department of Medicine, Hokkaido University, Japan.
Department of Cellular Pharmacology, Graduate School of Medicine, Hokkaido University, Japan.
Respir Med Case Rep. 2019 Feb 8;26:265-269. doi: 10.1016/j.rmcr.2019.02.007. eCollection 2019.
A recent case report described a case of pulmonary arterial hypertension (PAH) associated with use of the Chinese herbal medicine Qing-Dai; however, the clinical course and possible mechanisms have not been characterized. We present the case of a man with ulcerative colitis who was diagnosed with idiopathic PAH. After initiating oral beraprost therapy, the patient showed significant hemodynamic improvements and an unusual course of clinical recovery. In 2016, the Japanese Ministry of Health, Labour, and Welfare issued a warning regarding the possible side effects of Qing-Dai. We learned that our patient had been taking self-purchased Qing-Dai for 2 years. Therefore, we performed an experimental study and determined that Qing-Dai may cause PAH through a mechanism involving nitric oxide synthase inhibition and pulmonary artery endothelial dysfunction.
最近的一份病例报告描述了一例与使用中药青黛相关的肺动脉高压（PAH）病例；然而，其临床病程和可能的机制尚未明确。我们报告一例患有溃疡性结肠炎的男性患者，该患者被诊断为特发性PAH。在开始口服贝前列素治疗后，患者的血流动力学有显著改善，且临床恢复过程不同寻常。2016年，日本厚生劳动省发布了关于青黛可能存在副作用的警告。我们了解到我们的患者自行购买青黛服用了2年。因此，我们进行了一项实验研究，并确定青黛可能通过涉及一氧化氮合酶抑制和肺动脉内皮功能障碍的机制导致PAH。
